Ollendorf D - Search Results

1

The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States.

Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D, Bousvaros A, Grand RJ, Finkelstein JA. Kappelman MD, et al. Among authors: ollendorf d. Clin Gastroenterol Hepatol. 2007 Dec;5(12):1424-9. doi: 10.1016/j.cgh.2007.07.012. Epub 2007 Sep 29. Clin Gastroenterol Hepatol. 2007. PMID: 17904915

2

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, Finkelstein JA. Kappelman MD, et al. Among authors: ollendorf da. Gastroenterology. 2008 Dec;135(6):1907-13. doi: 10.1053/j.gastro.2008.09.012. Epub 2008 Sep 17. Gastroenterology. 2008. PMID: 18854185 Free PMC article.

3

Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease.

Kappelman MD, Porter CQ, Galanko JA, Rifas-Shiman SL, Ollendorf DA, Sandler RS, Finkelstein JA. Kappelman MD, et al. Among authors: ollendorf da. Inflamm Bowel Dis. 2011 Jan;17(1):62-8. doi: 10.1002/ibd.21371. Inflamm Bowel Dis. 2011. PMID: 20564532 Free PMC article.

4

Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.

Ollendorf DA, Lidsky L. Ollendorf DA, et al. Am J Ther. 2006 Nov-Dec;13(6):502-6. doi: 10.1097/01.mjt.0000245223.43783.45. Am J Ther. 2006. PMID: 17122530

5

Reduced mortality rates after intensive statin therapy in managed-care patients.

Fintel D, Joyce A, Mackell J, Graff J, Kuntze E, Ollendorf DA. Fintel D, et al. Among authors: ollendorf da. Value Health. 2007 Mar-Apr;10(2):161-9. doi: 10.1111/j.1524-4733.2006.00163.x. Value Health. 2007. PMID: 17391425 Free article.

6

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S. Ollendorf DA, et al. Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002. Clin Ther. 2009. PMID: 19446156

7

An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia.

Black L, Naslund MJ, Gilbert TD Jr, Davis EA, Ollendorf DA. Black L, et al. Among authors: ollendorf da. Am J Manag Care. 2006 Mar;12(4 Suppl):S99-S110. Am J Manag Care. 2006. PMID: 16551208 Free article.

8

Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis.

Ollendorf DA, Massarotti E, Birbara C, Burgess SM. Ollendorf DA, et al. J Manag Care Pharm. 2005 Jun;11(5):383-93. doi: 10.18553/jmcp.2005.11.5.383. J Manag Care Pharm. 2005. PMID: 15934797 Free PMC article.

9

Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.

Ollendorf DA, Peterson AN, Doyle J, Huse DM. Ollendorf DA, et al. Am J Manag Care. 2002 May;8(7 Suppl):S203-13. Am J Manag Care. 2002. PMID: 12022236 Free article.

10

Impact of atypical antipsychotics on outcomes of care in schizophrenia.

Joyce AT, Harrison DJ, Loebel AD, Ollendorf DA. Joyce AT, et al. Among authors: ollendorf da. Am J Manag Care. 2005 Sep;11(8 Suppl):S254-61. Am J Manag Care. 2005. PMID: 16180964 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

136 results

Search Page

Filters